[SCHEDULE 13G/A] Medicus Pharma Ltd. SEC Filing
Schedule 13G amendment filed by Armistice Capital, LLC and Steven Boyd discloses a shared beneficial ownership of 935,724 common shares of Medicus Pharma Ltd., representing 4.99% of the class. The filing states Armistice Capital acts as investment manager to Armistice Capital Master Fund Ltd., the direct holder, and that Mr. Boyd, as managing member, may be deemed to beneficially own the shares. Voting and dispositive power are reported as shared (935,724 shares) with no sole voting or dispositive power.
La modifica al Schedule 13G presentata da Armistice Capital, LLC e Steven Boyd indica una titolarit脿 beneficiaria condivisa di 935.724 azioni ordinarie di Medicus Pharma Ltd., pari al 4,99% della categoria. La comunicazione specifica che Armistice Capital agisce come gestore degli investimenti per Armistice Capital Master Fund Ltd., il titolare diretto, e che il sig. Boyd, in qualit脿 di membro dirigente, pu貌 essere considerato beneficiario delle azioni. Il potere di voto e il potere dispositvo sono dichiarati come condivisi (935.724 azioni), senza alcun potere di voto o dispositvo esclusivo.
La enmienda al Schedule 13G presentada por Armistice Capital, LLC y Steven Boyd revela una propiedad beneficiaria compartida de 935.724 acciones ordinarias de Medicus Pharma Ltd., que representan el 4,99% de la clase. La presentaci贸n indica que Armistice Capital act煤a como gestor de inversiones de Armistice Capital Master Fund Ltd., el titular directo, y que el Sr. Boyd, como miembro gerente, puede considerarse beneficiario de las acciones. El poder de voto y el poder dispositvo se informan como compartidos (935.724 acciones), sin poder de voto ni dispositvo exclusivo.
Armistice Capital, LLC鞕� Steven Boyd臧� 鞝滌稖頃� Schedule 13G 靾橃爼靹滌棎 霐半ゴ氅� Medicus Pharma Ltd.鞚� 氤错喌欤� 935,724欤茧ゼ 瓿惦彊鞙茧 鞁れ 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 頃措嫻 韥措灅鞀れ潣 4.99%鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滌棎電� Armistice Capital鞚� 歆侅爲 氤挫湢鞛愳澑 Armistice Capital Master Fund Ltd.鞚� 韴瀽甏�毽瀽搿� 頇滊彊頃橂┌, Boyd 鞌姅 甏�毽� 甑劚鞗愳溂搿滌劀 頃措嫻 欤检嫕鞚� 鞁れ鞝侅溂搿� 氤挫湢頃� 瓴冹溂搿� 臧勳＜霅� 靾� 鞛堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞚橁舶甓岅臣 觳橂秳甓岇潃 瓿惦彊鞙茧 鞁犼碃霅橃柎 鞛堨溂氅�(935,724欤�), 雼弲 鞚橁舶甓岇澊雮� 雼弲 觳橂秳甓岇潃 鞐嗢姷雼堧嫟.
Avenant au Schedule 13G d茅pos茅 par Armistice Capital, LLC et Steven Boyd r茅v茅lant une propri茅t茅 b茅n茅ficiaire partag茅e de 935 724 actions ordinaires de Medicus Pharma Ltd., repr茅sentant 4,99 % de la cat茅gorie. Le d茅p么t indique qu'Armistice Capital agit en tant que gestionnaire d'investissement pour Armistice Capital Master Fund Ltd., le d茅tenteur direct, et que M. Boyd, en tant que membre dirigeant, peut 锚tre consid茅r茅 comme propri茅taire b茅n茅ficiaire des actions. Le pouvoir de vote et le pouvoir de disposition sont d茅clar茅s comme 辫补谤迟补驳茅蝉 (935 724 actions), sans pouvoir de vote ou de disposition exclusif.
Die 脛nderung zum Schedule 13G eingereicht von Armistice Capital, LLC und Steven Boyd legt eine gemeinsame wirtschaftliche Eigent眉merschaft von 935.724 Stammaktien der Medicus Pharma Ltd. offen, was 4,99% der Klasse entspricht. Die Einreichung gibt an, dass Armistice Capital als Investmentmanager f眉r Armistice Capital Master Fund Ltd., den direkten Inhaber, fungiert und dass Herr Boyd als gesch盲ftsf眉hrendes Mitglied als wirtschaftlicher Eigent眉mer der Aktien angesehen werden kann. Stimm- und Verf眉gungsrechte werden als gemeinsam angegeben (935.724 Aktien), ohne alleinige Stimm- oder Verf眉gungsbefugnis.
- None.
- None.
Insights
TL;DR: Reporting persons hold a sub-5% stake, a routine disclosure with limited market impact.
The Schedule 13G/A shows a 4.99% position held indirectly via a master fund with voting and disposition powers exercised by Armistice Capital. Because the position is under the 5% threshold, the filing is consistent with passive investor reporting and does not signal an intent to influence control. The disclosure improves ownership transparency but is unlikely to materially affect valuation or trigger regulatory thresholds.
TL;DR: Governance implications are limited; shared voting power is disclosed but no control assertion is made.
The filing clarifies that the Master Fund is the direct holder while Armistice Capital and Steven Boyd exercise shared voting and dispositive power pursuant to an investment management agreement. The Master Fund expressly disclaims beneficial ownership by virtue of limited voting/disposition authority. This structure and the joint filing statement are standard for investment managers and do not indicate coordinated group control or a change in corporate governance.
La modifica al Schedule 13G presentata da Armistice Capital, LLC e Steven Boyd indica una titolarit脿 beneficiaria condivisa di 935.724 azioni ordinarie di Medicus Pharma Ltd., pari al 4,99% della categoria. La comunicazione specifica che Armistice Capital agisce come gestore degli investimenti per Armistice Capital Master Fund Ltd., il titolare diretto, e che il sig. Boyd, in qualit脿 di membro dirigente, pu貌 essere considerato beneficiario delle azioni. Il potere di voto e il potere dispositvo sono dichiarati come condivisi (935.724 azioni), senza alcun potere di voto o dispositvo esclusivo.
La enmienda al Schedule 13G presentada por Armistice Capital, LLC y Steven Boyd revela una propiedad beneficiaria compartida de 935.724 acciones ordinarias de Medicus Pharma Ltd., que representan el 4,99% de la clase. La presentaci贸n indica que Armistice Capital act煤a como gestor de inversiones de Armistice Capital Master Fund Ltd., el titular directo, y que el Sr. Boyd, como miembro gerente, puede considerarse beneficiario de las acciones. El poder de voto y el poder dispositvo se informan como compartidos (935.724 acciones), sin poder de voto ni dispositvo exclusivo.
Armistice Capital, LLC鞕� Steven Boyd臧� 鞝滌稖頃� Schedule 13G 靾橃爼靹滌棎 霐半ゴ氅� Medicus Pharma Ltd.鞚� 氤错喌欤� 935,724欤茧ゼ 瓿惦彊鞙茧 鞁れ 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 頃措嫻 韥措灅鞀れ潣 4.99%鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滌棎電� Armistice Capital鞚� 歆侅爲 氤挫湢鞛愳澑 Armistice Capital Master Fund Ltd.鞚� 韴瀽甏�毽瀽搿� 頇滊彊頃橂┌, Boyd 鞌姅 甏�毽� 甑劚鞗愳溂搿滌劀 頃措嫻 欤检嫕鞚� 鞁れ鞝侅溂搿� 氤挫湢頃� 瓴冹溂搿� 臧勳＜霅� 靾� 鞛堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞚橁舶甓岅臣 觳橂秳甓岇潃 瓿惦彊鞙茧 鞁犼碃霅橃柎 鞛堨溂氅�(935,724欤�), 雼弲 鞚橁舶甓岇澊雮� 雼弲 觳橂秳甓岇潃 鞐嗢姷雼堧嫟.
Avenant au Schedule 13G d茅pos茅 par Armistice Capital, LLC et Steven Boyd r茅v茅lant une propri茅t茅 b茅n茅ficiaire partag茅e de 935 724 actions ordinaires de Medicus Pharma Ltd., repr茅sentant 4,99 % de la cat茅gorie. Le d茅p么t indique qu'Armistice Capital agit en tant que gestionnaire d'investissement pour Armistice Capital Master Fund Ltd., le d茅tenteur direct, et que M. Boyd, en tant que membre dirigeant, peut 锚tre consid茅r茅 comme propri茅taire b茅n茅ficiaire des actions. Le pouvoir de vote et le pouvoir de disposition sont d茅clar茅s comme 辫补谤迟补驳茅蝉 (935 724 actions), sans pouvoir de vote ou de disposition exclusif.
Die 脛nderung zum Schedule 13G eingereicht von Armistice Capital, LLC und Steven Boyd legt eine gemeinsame wirtschaftliche Eigent眉merschaft von 935.724 Stammaktien der Medicus Pharma Ltd. offen, was 4,99% der Klasse entspricht. Die Einreichung gibt an, dass Armistice Capital als Investmentmanager f眉r Armistice Capital Master Fund Ltd., den direkten Inhaber, fungiert und dass Herr Boyd als gesch盲ftsf眉hrendes Mitglied als wirtschaftlicher Eigent眉mer der Aktien angesehen werden kann. Stimm- und Verf眉gungsrechte werden als gemeinsam angegeben (935.724 Aktien), ohne alleinige Stimm- oder Verf眉gungsbefugnis.
FAQ
What stake does Armistice Capital report in Medicus Pharma Ltd. (MDCX)?
Who holds voting and dispositive power over the reported shares?
Through which vehicle does Armistice Capital hold the Medicus Pharma shares?
Does the Schedule 13G/A indicate an intent to change control of Medicus Pharma?
Who signed the Schedule 13G/A on behalf of Armistice Capital?
